Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Leases (2022 - 2025)

Ovid Therapeutics (OVID) has disclosed Current Leases for 4 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 7.31% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, up 7.31%, and an annual FY2024 reading of $1.3 million, up 7.22% over the prior year.
  • Current Leases was $1.4 million for Q3 2025 at Ovid Therapeutics, up from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.4 million in Q3 2025 and bottomed at $533946.0 in Q4 2022.
  • Average Current Leases over 4 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • The sharpest move saw Current Leases surged 133.36% in 2023, then rose 7.2% in 2025.
  • Year by year, Current Leases stood at $533946.0 in 2022, then soared by 133.36% to $1.2 million in 2023, then increased by 7.22% to $1.3 million in 2024, then increased by 5.46% to $1.4 million in 2025.
  • Business Quant data shows Current Leases for OVID at $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.